You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MBG453

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome (MDS) Trial in Worldwide (HDM201, MBG453, Venetoclax)

Active, not recruiting
  • Acute Myeloid Leukemia (AML)
  • High-risk Myelodysplastic Syndrome (MDS)
  • Durham, North Carolina
  • +8 more
Dec 13, 2022

MDS, Leukemia, Myelomonocytic, Chronic Trial (decitabine, Spartalizumab, Sabatolimab)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic
  • (no location specified)
Aug 5, 2022

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in Worldwide (Decitabine, PDR001, MBG453)

Active, not recruiting
  • Leukemia
  • +7 more
  • Boston, Massachusetts
  • +10 more
Jan 19, 2023

Advanced Malignancies Trial in Worldwide (MBG453, PDR001, Decitabine)

Terminated
  • Advanced Malignancies
  • MBG453
  • +2 more
  • Baltimore, Maryland
  • +13 more
Sep 20, 2022

Glioblastoma Multiforme Trial in Stanford, Baltimore (MBG453)

Active, not recruiting
  • Glioblastoma Multiforme
  • MBG453
  • Stanford, California
  • +1 more
Nov 22, 2022

Acute Myeloid Leukemia Trial in Worldwide (MBG453, Venetoclax, Azacitidine)

Active, not recruiting
  • Acute Myeloid Leukemia
  • MBG453
  • +2 more
  • Birmingham, Alabama
  • +27 more
Jan 20, 2023

MDS, Acute Myeloid Leukemia Trial (Sabatolimab, Magrolimab, Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • (no location specified)
Sep 2, 2022

MDS Trial in Boston (MBG453)

Not yet recruiting
  • Myelodysplastic Syndromes
  • MBG453
  • Boston, Massachusetts
  • +2 more
Mar 28, 2021

Myelodysplastic Syndrome (MDS) Trial in United States (MBG453, Azacitidine, Decitabine)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • MBG453
  • +3 more
  • Chandler, Arizona
  • +22 more
Dec 5, 2022

MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)

Active, not recruiting
  • Myelodysplastic Syndromes
  • MBG453
  • +2 more
  • Duarte, California
  • +46 more
Jan 20, 2023

MDS Trial in Worldwide (MBG453, NIS793, canakinumab)

Recruiting
  • Myelodysplastic Syndromes
  • MBG453
  • +2 more
  • Duarte, California
  • +14 more
Jan 23, 2023

Primary Myelofibrosis, Myelofibrosis, PMF Trial (MBG453, NIS793, Spartalizumab)

Withdrawn
  • Primary Myelofibrosis
  • +4 more
  • MBG453
  • +3 more
  • (no location specified)
Mar 2, 2021

Acute Myeloid Leukemia Trial in Worldwide (Sabatolimab, Azacitidine)

Recruiting
  • Acute Myeloid Leukemia
  • Marseille, France
  • +11 more
Mar 29, 2022

Myelofibrosis Trial in Worldwide (Ruxolitinib, Siremadlin, Crizanlizumab)

Suspended
  • Myelofibrosis
  • Adelaide, South Australia, Australia
  • +37 more
Aug 18, 2022

Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)

Active, not recruiting
  • Myelodysplastic Syndrome (MDS)
  • Brasschaat, Belgium
  • +9 more
Jan 19, 2023

CHF Trial in Princeton (123I-mIBG (meta-iodobenzylguanidine))

Completed
Has Results
  • Heart Failure, Congestive
  • 123I-mIBG (meta-iodobenzylguanidine)
  • Princeton, New Jersey
    GE Healthcare
Feb 15, 2018